{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:17:35Z","timestamp":1760059055006,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Great Ormond Street Hospital Biomedical Research Centre","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"UK Medical Research Council","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"the Wellcome Trust","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"Institutional Strategic Support Fund\/UCL Therapeutic Acceleration Support (TAS)","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"the Sigrid Rausing Trust","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"the Jameel Education Foundation","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"RNID","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"LifeArc","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"GOSH Charity","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"SPARKS","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"Wellbeing of Women and Rosetrees","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]},{"name":"extramural research unit program of the South African Medical Research Council","award":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"],"award-info":[{"award-number":["562868","MR\/R025134\/1","MR\/R015325\/1","MR\/S009434\/1","MR\/N026101\/1","MR\/T044853\/1","MR\/T016809\/1","MR\/P026494\/1","204841\/Z\/16\/Z"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the GBA1 gene. Type 1 Gaucher disease is characterised by substrate accumulation in the visceral organs, which occurs in combination with acute and chronic neurodegeneration that distinguish type 2 and type 3 GD, respectively. We have previously shown the efficacy of neonatal AAV9 gene therapy for treating type 2 GD and aimed to investigate post-symptomatic administration into a model of type 1 disease. Current murine models of type 1 disease are limited in their recapitulation of early onset phenotypic manifestation and thus we aimed to create a novel model of type 1 in which to test the efficacy of adult gene therapy. Methods: The novel AAV-GD1 model was created through intracerebroventricular injection of AAV9 containing the human GBA1 gene under control of the neuron-specific synapsin promoter (AAV9.hSynI.hGBA1) to the pre-existing acute K14-lnl\/lnl model of type 2 GD. Administration of AAV9.hSynI.hGBA1 aimed to restore glucocerebrosidase expression in the brain and extend the lifespan beyond 14 days, allowing the visceral pathology to develop further. The organ pathology was characterised by immunohistochemistry at various time points. Once visceral disease was confirmed, an intravenous injection of AAV9 containing a ubiquitously active CAG promoter driving hGBA1 (AAV9.CAG.hGBA1) was administered to post-symptomatic mice. Animals were aged for 2 and 4 months post-treatment with AAV9.CAG.hGBA1, and immunohistochemistry and enzymatic activity were assessed to investigate therapeutic efficacy. Results: The AAV-GD1 model displayed visceral pathology in the spleen, lung, and liver from 2 months of age. This allowed us to validate the efficacy of adult gene therapy; intravenous administration of AAV9.CAG.hGBA1 transiently ameliorated the lung pathology and rescued the spleen pathology up to 4 months post-administration. Conclusions: The creation of the novel AAV-GD1 model with more aggressive visceral pathology presents a unique opportunity for investigation of new therapies to treat type 1 GD. AAV9.CAG.hGBA1 represents a potential therapeutic option for all forms of Gaucher disease.<\/jats:p>","DOI":"10.3390\/pharmaceutics17050650","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T07:46:49Z","timestamp":1747295209000},"page":"650","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generation and Treatment of a Novel Severe Model of Visceral Gaucher Disease by Genetic Therapy"],"prefix":"10.3390","volume":"17","author":[{"given":"Amy F.","family":"Geard","sequence":"first","affiliation":[{"name":"Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK"},{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-6082","authenticated-orcid":false,"given":"Giulia","family":"Massaro","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4149-8995","authenticated-orcid":false,"given":"Patrick","family":"Arbuthnot","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-4730","authenticated-orcid":false,"given":"Simon N.","family":"Waddington","sequence":"additional","affiliation":[{"name":"Wits\/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa"},{"name":"Maternal & Fetal Medicine, EGA Institute for Women\u2019s Health, Faculty of Population Health Sciences, University College London, London WC1E 6HU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-0949","authenticated-orcid":false,"given":"Ahad A.","family":"Rahim","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI105417","article-title":"Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher\u2019s disease","volume":"45","author":"Brady","year":"1966","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: Complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Roshan Lal, T., and Sidransky, E. (2017). The spectrum of neurological manifestations associated with Gaucher disease. Diseases, 5.","DOI":"10.3390\/diseases5010010"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic Gaucher disease: An intermediate phenotype between type 2 and type 3","volume":"143","author":"Schiffmann","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jimd.12235","article-title":"The definition of neuronopathic Gaucher disease","volume":"43","author":"Schiffmann","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","article-title":"Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes","volume":"132","author":"Daykin","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"114402","DOI":"10.1016\/j.addr.2022.114402","article-title":"Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease","volume":"187","author":"Horowitz","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Schiffmann","year":"2004","journal-title":"J. Med. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11318540-000000000-00000","article-title":"Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease","volume":"24","author":"Pastores","year":"2010","journal-title":"BioDrugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","article-title":"Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy","volume":"93","author":"Aerts","year":"2008","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ymgme.2021.06.009","article-title":"Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma","volume":"133","author":"Ramaswami","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-017-1541-7","article-title":"Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: Two case reports","volume":"12","author":"Amato","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1310\/hpj5107-553","article-title":"Enzyme replacement or substrate reduction? A review of Gaucher disease treatment options","volume":"51","author":"Holsopple","year":"2016","journal-title":"Hosp. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: A clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00219337","article-title":"Quantitative correlation between the residual activity of \u03b2-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease","volume":"88","author":"Leinekugel","year":"1992","journal-title":"Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"ref_20","first-page":"3038","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Castillon, G., Chang, S.-C., and Moride, Y. (2022). Global incidence and prevalence of Gaucher disease: A targeted literature review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010085"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid \u03b2-glucosidase deficiency: The defect in Gaucher disease","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/hum.2018.072","article-title":"Delivery of Glucosylceramidase Beta gene using AAV9 vector therapy as a treatment strategy in mouse models of Gaucher disease","volume":"30","author":"Du","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/hmg\/ddz317","article-title":"Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes","volume":"29","author":"Massaro","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","first-page":"1467","article-title":"Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease","volume":"33","author":"Massaro","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21926\/obm.genet.2203165","article-title":"Newborn screening in Gaucher disease: A bright and complicated future","volume":"6","author":"Ryan","year":"2022","journal-title":"OBM Genet."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kim, J.-Y., Grunke, S.D., Levites, Y., Golde, T.E., and Jankowsky, J.L. (2014). Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. J. Vis. Exp. JoVE, 51863.","DOI":"10.3791\/51863-v"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations: A review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Control. Clin. Trials"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/gt.2011.157","article-title":"In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression","volume":"19","author":"Rahim","year":"2012","journal-title":"Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI0214530","article-title":"Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage","volume":"109","author":"Mizukami","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","article-title":"Resting energy expenditure in Gaucher\u2019s disease type 1: Effect of Gaucher\u2019s cell burden on energy requirements","volume":"38","author":"Barton","year":"1989","journal-title":"Metabolism"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Schiffer, V., Santiago-Mujika, E., Flunkert, S., Schmidt, S., Farcher, M., Loeffler, T., Schilcher, I., Posch, M., Neddens, J., and Sun, Y. (2020). Characterization of the visceral and neuronal phenotype of 4L\/PS-NA mice modeling Gaucher disease. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227077"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.omtm.2020.11.018","article-title":"Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector","volume":"20","author":"Dahl","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/mt.2015.16","article-title":"Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice","volume":"23","author":"Dahl","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_39","first-page":"719","article-title":"AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease","volume":"8","author":"McEachern","year":"2006","journal-title":"J. Gene Med. Cross-Discip. J. Res. Sci. Gene Transf. Its Clin. Appl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","article-title":"Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8","volume":"14","author":"Inagaki","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1096\/fj.14-269092","article-title":"Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates","volume":"29","author":"Mattar","year":"2015","journal-title":"FASEB J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101619","DOI":"10.1016\/j.xcrm.2024.101619","article-title":"Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases","volume":"5","author":"Esposito","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/gt.2017.75","article-title":"Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler\u2013Najjar Syndrome Type I","volume":"24","author":"Bortolussi","year":"2017","journal-title":"Gene Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.125.2.509","article-title":"Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial","volume":"125","author":"Moss","year":"2004","journal-title":"Chest"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/gt.2008.68","article-title":"Clinical gene therapy using recombinant adeno-associated virus vectors","volume":"15","author":"Mueller","year":"2008","journal-title":"Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.sempedsurg.2012.10.010","article-title":"Stem cell and genetic therapies for the fetus","volume":"22","author":"Pearson","year":"2013","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"397879","DOI":"10.1155\/2015\/397879","article-title":"Evidence for Contribution of CD4+ CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery","volume":"2015","author":"Nivsarkar","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/gt.2011.200","article-title":"AAV-based neonatal gene therapy for hemophilia A: Long-term correction and avoidance of immune responses in mice","volume":"19","author":"Hu","year":"2012","journal-title":"Gene Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1128\/JVI.74.3.1524-1532.2000","article-title":"Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes","volume":"74","author":"Halbert","year":"2000","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/hum.2009.157","article-title":"Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia","volume":"21","author":"Weinstein","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood-2004-10-3867","article-title":"Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2\/8-mediated, liver-directed gene therapy","volume":"105","author":"Wang","year":"2005","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/gt.2008.170","article-title":"Tailoring the AAV vector capsid for gene therapy","volume":"16","author":"Vandenberghe","year":"2009","journal-title":"Gene Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41434-024-00476-8","article-title":"Efficacy of an AAV vector encoding a thermostable form of glucocerebrosidase in alleviating symptoms in a Gaucher disease mouse model","volume":"31","author":"Milenkovic","year":"2024","journal-title":"Gene Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1111\/febs.16758","article-title":"Design of a stable human acid-\u03b2-glucosidase: Towards improved Gaucher disease therapy and mutation classification","volume":"290","author":"Pokorna","year":"2023","journal-title":"FEBS J."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/5\/650\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:33:15Z","timestamp":1760031195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/5\/650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["pharmaceutics17050650"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17050650","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}